Investigating immune responses in viral pneumonia and ARDS
Official title: Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome
Run by University Hospital, Tours · NCT06720818 · Data updated 2026-11-12
This study looks at how certain immune cells behave in patients with viral pneumonia and ARDS to see if understanding them can help create better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University Hospital, Tours Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tours) |
| Status | Recruiting |
| Started | May 5, 2025 |
| Main results expected | February 2029 |
| Study ends | February 2029 |
| Registry record updated | May 29, 2025 |
| Trial ID | NCT06720818 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are admitted to critical care for viral pneumonia or other specified conditions leading to ARDS.
✕Probably not a fit
Patients with severe immunosuppression may not benefit from this study due to their compromised immune response.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on understanding the role of Mucosal Associated Invariant T (MAIT) cells in patients suffering from viral pneumonia and Acute Respiratory Distress Syndrome (ARDS). The study aims to dissect the immunopathology of ARDS, particularly in cases related to SARS-CoV-2 and influenza A virus, to identify potential endotypes that could benefit from targeted therapies. By analyzing the activation mechanisms and functions of MAIT cells, the researchers hope to provide insights that could lead to new precision-medicine approaches for treating ARDS. Patients admitted to critical care units for specific conditions will be monitored to gather data on immune responses and tissue repair processes.
Why it matters
Potential benefit: If successful, this study could lead to the development of individualized therapies for patients with ARDS, improving their chances of recovery.
How similar studies have gone: While the role of MAIT cells in ARDS is being explored, this specific approach is relatively novel and has not been extensively tested in previous studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Patients admitted to critical care (Intensive Care Unit, Continuous Monitoring Unit, Intensive Care Unit) at the CHRU de Tours * Patients admitted to critical care for one of the following reasons: * Acute community-acquired pulmonary infection (pneumonia), * Severe acute pancreatitis, with onset of ARDS criteria less than 48 hours ago, * Severe isolated head injury requiring invasive mechanical ventilation, * Severe burn defined by a burned surface area exceeding 20% and/or deep lesions exceeding 3% of the total body surface area, with the onset of ARDS criteria less than 48 hours ago, * Patient admitted to Intensive Care Medicine, requiring invasive mechanical ventilation, * Patient admitted to cardiac surgery for scheduled surgery for valve replacement and/or coronary artery bypass grafting, with inclusion the day before surgery, Non-inclusion criteria : * Patients with severe immunosuppression (impairing the ability to analyse the immune response, particularly T lymphocytes): active haematological malignancy, solid organ transplantation or bone marrow transplantation, systemic immunosuppressive treatment, ongoing chemotherapy (including immune checkpoint inhibitors). * Person who has objected to data processing * Patient under guardianship or curatorship
Where it's running
-
University hospital
Tours, France Recruiting
Study contacts
- Study coordinator: Youenn JOUAN, Dr
- Email: youenn.jouan@gmail.com
- Phone: 0247474038
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding immune patterns and ECMO strategies to help adults with severe ARDS
This study tests how different immune and clinical patterns in adults with moderate-to-severe ARDS respond to ECMO and lung-protective care, aiming to improve outcomes.
-
Optimal corticosteroid dosing for ARDS: short vs. prolonged therapy
This trial tests different corticosteroid doses and treatment lengths to see which helps adults with ARDS who are on ventilators.
-
Lateral positioning to optimize breathing in adults after abdominal surgery with ARDS
This study tests whether lying on the left or right side helps improve lung function in adults who developed ARDS after abdominal surgery, using a bedside imaging test to watch ventilation and blood flow while changing positions.
-
Dexamethasone for sepsis-related ARDS in adults on ventilatory support
This trial tests whether dexamethasone can help adults with sepsis-associated ARDS on ventilators recover better compared to placebo.
-
NIRS for EDResp: Which first helps hypoxemic adults best?
This trial tests whether non-invasive ventilation with a mask (NIPPV) or high-flow nasal oxygen (HFNO) is more helpful for adults in the emergency department with acute hypoxemic respiratory failure.
-
Sodium bicarbonate with bedside electrical impedance tomography to map lung blood flow in ventilated adults
This project will try whether a small sodium bicarbonate injection combined with bedside electrical impedance tomography can map lung blood flow in adults on mechanical ventilation, compared with hypertonic saline.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.